C9H9F2N HCl Ticagrelor Intermediates CAS 1156491 10 9 cGMP standard

CAS : 1156491-10-9 Ticagrelor Intermediate C9H9F2N HCl cGMP standard

Chemical Name : Cyclopropanamine , 2 - ( 3 , 4 - difluorophenyl ) - , Hydrochloride ( 1 : 1 ) ; ( 1R , 2S ) - REL - , ( 1R , trans ) - 2 - ( 3 , 4 -difluorophenyl ) cyclopropane amine

Molecular Formula : C9H10ClF2N

Molecular Weight : 205.63

Usage : Ticagrelor Intermediate

Description :

Ticagrelor is the active pharmaceutical ingredient of Brilinta, Brilique or Possia, which is used to prevent thrombotic events such as heart attack or stroke in people who has acute coronary syndrome or myocardial infarction with ST elevation. It is produced by AstraZeneca. On Dec 30, 2010, it was approved by Europe Commission and on July 20, 2011 approved by US FDA. The global anual sales of Brilinta/Brilique is more than USD1 billion.

4 , 6 - Dichloro - 5 - Nitro - 2 - propylthiopyrimidine CAS No . : 145783-14-8 is one of its intermediates. There are several synthesis routes to manufacture this intermediate but some routes are protected by the patents in some countries including Europe, USA and China. We strictly obey the laws and our commercial products are manufactured without infringing such patents. But anyway, the buyers should know the patent status by themselves. We promise to supply the real route of synthesis to the buyers. The buyers should take the risks of patent infringement by themselves.

Competitive Advantage: Produced under cGMP conditions, support customers’ registrations.